Loading clinical trials...
Loading clinical trials...
A Randomized, Double-blind, Placebo-controlled, Multi-dose Phase 2 Study to Evaluate the Efficacy, Safety and Tolerability of Romosozumab in the Treatment of Japanese Women With Postmenopausal Osteoporosis
The purpose of this study is to determine if treatment with romosozumab increases bone mineral density in Japanese women with postmenopausal osteoporosis.
Age
55 - 85 years
Sex
FEMALE
Healthy Volunteers
No
Research Site
Anjyo-shi, Aichi-ken, Japan
Research Site
Fukuoka, Fukuoka, Japan
Research Site
Kitakyushu-shi, Fukuoka, Japan
Research Site
Yanagawa-shi, Fukuoka, Japan
Research Site
Mizunami-shi, Gifu, Japan
Research Site
Sapporo, Hokkaido, Japan
Research Site
Sapporo, Hokkaido, Japan
Research Site
Morioka, Iwate, Japan
Research Site
Yokohama, Kanagawa, Japan
Research Site
Yokohama, Kanagawa, Japan
Start Date
October 12, 2012
Primary Completion Date
October 9, 2014
Completion Date
June 17, 2015
Last Updated
March 25, 2019
252
ACTUAL participants
Romosozumab
DRUG
Placebo
DRUG
Lead Sponsor
Amgen
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions